Zacks Research Brokers Lower Earnings Estimates for BIO

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Friday, May 22nd. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.34 per share for the quarter, down from their previous forecast of $2.38. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.42 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2027 earnings at $2.39 EPS.

Several other equities analysts also recently issued reports on BIO. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a report on Friday, May 15th. They issued an “outperform” rating and a $320.00 price objective on the stock. Weiss Ratings cut Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research note on Friday, May 1st. Finally, Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Hold” and a consensus target price of $303.33.

Bio-Rad Laboratories Trading Up 3.1%

Shares of NYSE:BIO opened at $296.52 on Wednesday. The business’s 50 day moving average price is $275.82 and its 200-day moving average price is $291.91. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $343.12. The firm has a market capitalization of $7.93 billion, a price-to-earnings ratio of 48.85 and a beta of 1.06. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.54 EPS.

Institutional Trading of Bio-Rad Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First Eagle Investment Management LLC boosted its position in shares of Bio-Rad Laboratories by 2.0% during the 4th quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock valued at $778,828,000 after acquiring an additional 50,154 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Bio-Rad Laboratories by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after purchasing an additional 12,251 shares during the period. Earnest Partners LLC boosted its holdings in Bio-Rad Laboratories by 0.6% in the 3rd quarter. Earnest Partners LLC now owns 609,284 shares of the medical research company’s stock valued at $170,837,000 after purchasing an additional 3,398 shares during the last quarter. Capital Research Global Investors grew its position in Bio-Rad Laboratories by 18.2% in the fourth quarter. Capital Research Global Investors now owns 494,472 shares of the medical research company’s stock worth $149,820,000 after acquiring an additional 76,117 shares during the period. Finally, Bank of America Corp DE increased its stake in Bio-Rad Laboratories by 1.7% during the third quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after acquiring an additional 7,754 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.